SCHEMBL2852272

SCHEMBL2852272

CCOC(=O)N1CCC(n2nc(C)cc2C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
KDM5A P29375 1/20 0.48
GAA P10253 2/20 0.47
ALOX12 P18054 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CHRM1 P11229 1/20 0.47
TSHR P16473 1/20 0.46
NOS2 P35228 4/20 0.45
NOS1 P29475 3/20 0.45
NOS3 P29474 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
KDM5C P41229 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
KDM3A Q9Y4C1 1/20 0.44
TP53 P04637 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
THRB P10828 1/20 0.43
ATM Q13315 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15942061 0.86 KCNH2 (0.54) L3MBTL1KDM5AGAAALOX12SMN1; SMN2
SCHEMBL2855921 0.81 DRD2 (0.61) L3MBTL1GAASMN1; SMN2TSHRNOS2
SCHEMBL2579784 0.81 ALDH1A1 (0.48) L3MBTL1SMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL2579788 0.81 ALDH1A1 (0.48) L3MBTL1SMN1; SMN2TSHRKDM4EALDH1A1
SCHEMBL24880479 0.77 GPR119 (0.46) GAASMN1; SMN2KDM4EALDH1A1TP53
SCHEMBL29150097 0.77 L3MBTL1 (0.52) L3MBTL1GAAALOX12SMN1; SMN2CHRM1
SCHEMBL15951012 0.76 KDM5A (0.45) KDM5ATHRB
SCHEMBL15935405 0.75 SMN1; SMN2 (0.41) L3MBTL1KDM5AGAASMN1; SMN2KDM4E
SCHEMBL13135665 0.74 ALOX15 (0.51) L3MBTL1KDM5AGAASMN1; SMN2
SCHEMBL18161205 0.74 SMN1; SMN2 (0.56) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-100341862-C Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORP (JP) 2007-10-10 CN disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 L3MBTL1 1646/4885KDM5A 1393/4885GAA 492/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 L3MBTL1 1440/4885KDM5A 1393/4885GAA 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.